US 11,738,064 B2
Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
Seong Beom Kim, Gyeonggi-do (KR); Hyei Yoon Jung, Seoul (KR); Seok Woo Yang, Gyeonggi-do (KR); Hyuk Sang Kwon, Seoul (KR); Jae-Hoon Kang, Seoul (KR); and Yong-Sung Kim, Gyeonggi-do (KR)
Assigned to ILDONG PHARM CO., LTD., Seoul (KR)
Filed by ILDONG PHARM CO., LTD., Seoul (KR)
Filed on Mar. 17, 2021, as Appl. No. 17/204,311.
Application 17/204,311 is a continuation of application No. 15/720,016, filed on Sep. 29, 2017, granted, now 11,052,130.
Application 15/720,016 is a continuation of application No. PCT/KR2016/003254, filed on Mar. 30, 2016.
Claims priority of application No. 10-2015-0045684 (KR), filed on Mar. 31, 2015.
Prior Publication US 2021/0220436 A1, Jul. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 38/17 (2006.01); A61K 38/16 (2006.01); A61K 47/64 (2017.01); A61K 39/00 (2006.01); A61P 27/02 (2006.01); A61P 43/00 (2006.01); A61K 38/18 (2006.01); C07K 14/475 (2006.01)
CPC A61K 38/179 (2013.01) [A61K 38/16 (2013.01); A61K 38/1866 (2013.01); A61K 39/001135 (2018.08); A61K 39/395 (2013.01); A61K 47/64 (2017.08); A61P 27/02 (2018.01); A61P 43/00 (2018.01); C07K 14/475 (2013.01); C07K 2319/74 (2013.01)] 9 Claims
 
1. A ranibizumab mutant comprising the light chain amino acid sequence SEQ ID NO: 8 and the heavy chain amino acid sequence SEQ ID NO: 10.